Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot Feasibility Trial of the Tolerability of Oral Salvia Hispanica and Its Effect on Blood Fatty Acids and Stool Microbiome in Patients With Treated Non-Hodgkin Lymphoma

NCT02652715 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT02652715
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02652715 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot Feasibility Trial of the Tolerability of Oral Salvia Hispanica and Its Effect on Blood Fatty Acids and Stool Microbiome in Patients With Treated Non-Hodgkin Lymphoma
Lead sponsor
Mayo Clinic
Phase
Not applicable
Overall status
Completed
Start date
January 19, 2016
Completion date
November 12, 2019
Enrollment
29 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adult nasal type extranodal nk/t-cell lymphoma, adult t-cell leukemia/lymphoma, anaplastic large cell lymphoma, angioimmunoblastic t-cell lymphoma, b lymphoblastic leukemia/lymphoma, blastic plasmacytoid dendritic cell neoplasm, burkitt leukemia, central nervous system lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, diffuse large b-cell lymphoma, enteropathy-associated t-cell lymphoma, extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue, grade 1 follicular lymphoma, grade 2 follicular lymphoma, grade 3 follicular lymphoma, hepatosplenic t-cell lymphoma, lymphoplasmacytic lymphoma, mantle cell lymphoma, mediastinal (thymic) large b-cell lymphoma, mycosis fungoides, nasal type extranodal nk/t-cell lymphoma, nodal marginal zone lymphoma, peripheral t-cell lymphoma, not otherwise specified, post-transplant lymphoproliferative disorder, primary cutaneous anaplastic large cell lymphoma, primary effusion lymphoma, sezary syndrome, splenic marginal zone lymphoma, subcutaneous panniculitis-like t-cell lymphoma, systemic anaplastic large cell lymphoma, t lymphoblastic leukemia/lymphoma, transformed recurrent non-hodgkin lymphoma